How to locate your baseline weight from when you started a GLP-1 receptor agonist like semaglutide or tirzepatide, why it matters for tracking progress, and what to do if the number is missing.
A single high-carb cheat day can knock you out of ketosis within hours. Learn how long it takes to re-enter ketosis, what happens metabolically, and how to minimize the damage.
How BPC-157 pentadecapeptide influences comprehensive metabolic panel markers including liver enzymes, kidney function, electrolytes, and glucose. Evidence-based monitoring guidance.
Enclomiphene citrate raises estradiol (sensitive) by 40 to 60% in most men as testosterone increases. Learn the mechanism, expected magnitude, monitoring timeline, and when to act on elevated levels.
Enclomiphene citrate raises free testosterone by blocking estrogen receptors in the hypothalamus, restoring LH-driven testicular production. Learn about magnitude, timeline, and monitoring.
How finasteride affects your comprehensive metabolic panel results, including liver enzymes, kidney markers, electrolytes, and glucose. Evidence-based monitoring guidance for patients on finasteride.
Finasteride PSA calculator: multiply your measured PSA by 2 to estimate the true value. Finasteride lowers PSA by about 50% after 6 to 12 months of use.
Metformin typically lowers or stabilizes AST levels. Learn the clinical evidence behind metformin's effect on liver enzymes, when to monitor, and what elevated AST on metformin means.
Tirzepatide (Mounjaro) measurably shifts triglycerides, LDL cholesterol, and HDL. Learn the magnitude, timing, mechanism, and when to recheck your lipid panel on treatment.
Ozempic (semaglutide) lowers fasting triglycerides by 12 to 22% in clinical trials. Learn the mechanism, timeline, expected magnitude, and monitoring schedule for triglyceride changes on semaglutide.
Testosterone cypionate raises red blood cell counts, shifts white cell ratios, and can trigger polycythemia. Learn the magnitude, timeline, and monitoring schedule backed by clinical trial data.
Testosterone cypionate raises free testosterone by saturating SHBG binding capacity. What is established about magnitude and time course, what remains unverified, and how clinicians use trough free testosterone to guide dosing.
Testosterone cypionate changes HDL, LDL, total cholesterol, and triglycerides in predictable ways. Learn the direction, magnitude, timing, and monitoring schedule backed by RCT data.
Testosterone cypionate raises total testosterone predictably. Learn the magnitude of increase, time course to steady state, optimal monitoring windows, and dose-response data from clinical trials.
Semaglutide 2.4 mg (Wegovy) changes multiple CMP markers, including fasting glucose, liver enzymes, kidney function, and electrolytes. Here is what the clinical trial data shows and when to recheck labs.
Clinical evidence on how Zepbound (tirzepatide) affects estimated glomerular filtration rate (eGFR), including trial data, magnitude of change, monitoring timelines, and what the numbers mean for kidney health.
Zepbound (tirzepatide) significantly lowers fasting insulin levels through dual GIP/GLP-1 receptor activity. Learn the magnitude, timeline, mechanism, and monitoring strategy backed by SURMOUNT trial data.
Tirzepatide (Zepbound) lowers fasting triglycerides by 20 to 30% in clinical trials. Learn the mechanism, timeline, expected magnitude, and monitoring schedule.
Evidence-based monitoring guide for inclisiran (Leqvio) in adults aged 30 to 49, covering lipid panels, liver function tests, injection-site checks, and long-term follow-up schedules.
A clinical review of insulin glargine (Lantus) manufacturing processes, supply chain structure, historical shortages, biosimilar competition, and current availability for diabetes management.
Clinical guide to combining alprostadil (Caverject/MUSE) with prednisone: pharmacokinetic and pharmacodynamic interactions, monitoring parameters, dose adjustments, and patient counseling.
Clinical review of the alprostadil and pregabalin drug interaction, covering pharmacodynamic overlap, hypotension risk, monitoring parameters, and dose-adjustment guidance.
A source-audited review of the interaction between AndroGel (testosterone gel) and hormonal contraceptives, covering secondary exposure risk, plausible pharmacokinetic overlap, hormonal opposition in transmasculine patients, and what clinicians should verify before making a monitoring plan.
Clinical review of the interaction between AndroGel (testosterone gel) and proton pump inhibitors like omeprazole and pantoprazole, covering pharmacokinetics, safety data, and monitoring recommendations.
Clinical review of potential interactions between AOD-9604 (HGH fragment 176-191) and hormonal contraceptives, covering pharmacokinetic mechanisms, safety data, and monitoring recommendations.
Can you take AOD-9604 with gabapentin? A guide covering pharmacokinetic and pharmacodynamic interactions, monitoring parameters, dose adjustments, and patient counseling.
Can you take AOD-9604 (HGH fragment 176-191) with testosterone? A guide covering pharmacology, safety data, monitoring protocols, and dose considerations.
Can you take BPC-157 with acetaminophen? Review of hepatic metabolism overlap, CYP450 considerations, severity assessment, monitoring parameters, and dose-adjustment guidance for this peptide-analgesic combination.
Expert analysis of the BPC-157 pentadecapeptide and apixaban (Eliquis) interaction, covering CYP3A4/P-gp mechanisms, bleeding risk, severity rating, monitoring parameters, and dose-adjustment considerations.
Can you take BPC-157 with pregabalin? A analysis of pharmacokinetic and pharmacodynamic interactions, monitoring protocols, and dose-adjustment considerations.
Can you take BPC-157 with simvastatin? Review the pharmacokinetic and pharmacodynamic interaction profile, CYP3A4 considerations, monitoring protocols, and clinical recommendations.
Board-reviewed guide to the bremelanotide (Vyleesi) and opioid interaction, covering mechanism, severity, CNS depression risk, monitoring, dose adjustment, and patient counseling.
Can you take Vyleesi (bremelanotide) with pregabalin? Review the pharmacokinetic and pharmacodynamic interaction profile, blood pressure risks, CNS effects, and monitoring recommendations.
Can you take Vyleesi (bremelanotide) with sildenafil? A guide to the pharmacodynamic interaction, blood pressure risks, monitoring protocols, and dose-adjustment strategies.
A clinician-oriented review of taking Cialis (tadalafil) with levothyroxine, covering pharmacokinetic and pharmacodynamic mechanisms, evidence status, monitoring, dose timing, and what still needs primary-source verification.
Evidence-based review of CJC-1295 (modified GRF 1-29) interactions with hormonal contraceptives including oral pills, patches, and rings. Covers pharmacokinetic and pharmacodynamic mechanisms, severity rating, monitoring parameters, and dose adjustments.
Can you take CJC-1295 with diphenhydramine? A guide covering pharmacodynamic interactions, sleep-architecture effects on GH release, monitoring parameters, and dose-timing strategies.
Can you take CJC-1295 modified GRF with proton pump inhibitors like omeprazole or pantoprazole? A analysis of pharmacokinetic overlap, gastric pH effects, monitoring protocols, and dose-adjustment considerations.
Can you take CJC-1295 modified GRF with tadalafil? Review the pharmacokinetic and pharmacodynamic interaction profile, monitoring protocols, and dose-adjustment guidance backed by primary literature.
Taking Farxiga and finasteride together: compare their interactions, side effects, kidney monitoring, PSA interpretation and surgery instructions.
Farxiga and metformin have no drug interaction and are safely combined, lowering A1C by about 2 points with low hypoglycemia risk without insulin.
Can you take Farxiga (dapagliflozin) with tadalafil? A guide covering the pharmacokinetic and pharmacodynamic interaction profile, blood pressure monitoring, and dose adjustments.
Clinical guide to combining dapagliflozin (Farxiga) with testosterone therapy. Covers pharmacokinetic and pharmacodynamic interactions, polycythemia risk, lipid effects, and monitoring protocols.
Is it safe to take Prolia (denosumab) with tadalafil? A guide covering drug interaction mechanisms, monitoring protocols, and dose considerations.
Dulaglutide (Trulicity) and prednisone have a pharmacodynamic interaction that can raise blood glucose. Learn about the mechanism, monitoring, dose adjustments, and clinical evidence.
Can you take Trulicity (dulaglutide) with sildenafil? A guide covering the pharmacokinetic and pharmacodynamic interaction profile, blood pressure monitoring, dose adjustments, and patient counseling.
A source-audited look at the dutasteride (Avodart) and acetaminophen interaction, covering metabolic pathways, hepatic safety considerations, and what remains unverified.
Evidence-based review of the dutasteride and apixaban drug interaction, including CYP3A4/P-gp mechanism, severity rating, monitoring labs, dose adjustments, and patient counseling.
Can you take Avodart (dutasteride) with gabapentin? A guide covering mechanism, severity, monitoring, dose adjustment, and patient counseling for this drug combination.
Can you take dutasteride (Avodart) with omeprazole or pantoprazole? A guide covering CYP3A4 metabolism, absorption effects, severity ratings, and dose-adjustment recommendations.
Can you take Avodart (dutasteride) with tadalafil? What the pharmacology and BPH combination-therapy evidence actually support, what remains unverified, and where a third drug changes the risk picture.
Evidence-based analysis of the dutasteride-warfarin drug interaction, covering CYP metabolism, bleeding risk, INR monitoring protocols, and practical prescribing considerations.
Clinical review of the drug interaction between empagliflozin (Jardiance) and finasteride, covering CYP metabolism, pharmacodynamic overlap, monitoring parameters, and dose-adjustment guidance.
Evidence-based review of the empagliflozin (Jardiance) and sildenafil drug interaction, covering pharmacokinetic and pharmacodynamic mechanisms, blood pressure monitoring, and dose adjustment recommendations.
Can you take Jardiance (empagliflozin) with tadalafil? Review the pharmacokinetic and pharmacodynamic interaction profile, blood pressure effects, monitoring parameters, and dose-adjustment guidance backed by FDA labels and primary literature.
Can you take Jardiance (empagliflozin) with testosterone? A guide covering pharmacokinetic and pharmacodynamic interactions, monitoring protocols, and dose-adjustment considerations.
Clinical analysis of the enclomiphene citrate and benzodiazepines interaction, including CYP metabolism overlap, CNS effects, severity rating, monitoring parameters, and dose-adjustment guidance.
Can you take enclomiphene citrate with ibuprofen or naproxen? A review of the pharmacokinetic overlap, thromboembolic and renal considerations, and what monitoring is reasonable for this combination.
Can you take enclomiphene citrate with omeprazole or pantoprazole? Review the pharmacokinetic interaction profile, CYP enzyme overlap, absorption considerations, and clinical monitoring recommendations.
Can you take enclomiphene citrate with rosuvastatin? What is established about their separate metabolic pathways, what remains unproven, and what a clinician should verify before co-prescribing.